NaviCyte Scientific holds the exclusive commercial distribution rights to the Caco-2TM cell line as deposited by the Memorial Sloan-Kettering Cancer Center (SK) with the American Type Culture Collection (ATCC) under ATCC catalog entry HTB-37.  Note:  All uses of Caco-2TM cells, other than for research by a non-profit or academic entity, require a license and use authorization from NaviCyte Scientific under its exclusive arrangement with Memorial Sloan-Kettering -- even for cells obtained from ATCC.  Caco-2TM cells may not be distributed or used for any commercial uses without the prior written authorization of NaviCyte Scientific.  Please see below for more information. NaviCyte's Exclusive Commercial Rights to CACO-2. The Caco-2TM cell line originated in the laboratories of the Memorial Sloan-Kettering Cancer Center (SK) in 1974. Shortly thereafter, SK deposited Caco-2TM with the American Type Culture Collection (ATCC) as the sole distributor of Caco-2TM to the non-profit research community. This deposit was made subject to explicit restrictions to the effect that Caco-2TM cells would not be utilized by any third party for commercial purposes or redistributed by anyone without SK's prior approval. ATCC routinely informs its customers that the Caco-2TM cell line distributed by ATCC is restricted to non-commercial research uses only, including through conspicuous notices in its product catalogs (under ATCC's "HTB-37" classification for Caco-2TM) and in its order form. Unauthorized commercial uses include any uses of Caco-2TM by a for-profit entity, including in particular the use of Caco-2TM in R&D and drug discovery activities of a life sciences company, and reselling of Caco-2TM cells, any patent filings based on research utilizing Caco-2TM and any fee-for-research services offering involving Caco-2TM. SK has granted to NaviCyte Scientific the exclusive license and right to distribute the Caco-2TM cell line to third parties for commercial uses. SK routinely refers any interested commercial entities to NaviCyte. NaviCyte will provide written confirmation from SK of NaviCyte's exclusive commercial distribution rights to Caco-2TM upon request. NaviCyte has entered into a number of non-exclusive internal use licenses granting the right to use Caco-2TM for commercial purposes, including the right to culture the Caco-2TM cells. Commercial agreements include (among others): Abbott Laboratories ADMETRx, Inc. Amaxa GmbH Astellas AstraZeneca BD Biosciences Discovery Labware Bristol-Myers Squibb Biogen Idec Diagnostic Hybrids ICOS Corporation In Vitro Technologies Labopharm MannKind Corporation Merck & Co. Microbia Millennium Pharmaceuticals Millipore Corporation Nastech Pharmaceutical Company Novartis Pfizer Procter & Gamble Pharmaceuticals A major U.S.-based biotechnology company (with market cap of $50+ billion) A major U.S.-based life science company (with a market cap of $1.5+ billion) A large multinational pharmaceutical company Warner-Lambert Company Zealand Pharma Since the original Caco-2TM cell line was deposited exclusively with ATCC for distribution for non-profit purposes, and NaviCyte holds the exclusive rights to grant commercial use licenses to Caco-2TM, any use of Caco-2TM by a for-profit entity may constitute an unauthorized use, unless the proper license and authorization for this use has been obtained directly from NaviCyte. The Caco-2Up-To-Date Initiative NaviCyte has commenced the Caco-2Up-To-Date initiative, a coordinated initiative to bring companies’ use of Caco-2™ into compliance without a penalty. Companies who wish to take advantage of the benefits offered by the Caco-2Up-To-Date program must enter into a license and commercial use agreement with NaviCyte which covers their future uses of the Caco-2TM cell line as well as any unauthorized past uses. License and use fees are payable for annual or perpetual uses and payment terms may be coordinated with the company’s research budget. If you would like to obtain or use Caco-2TM cells for any commercial purposes whatsoever, please contact NaviCyte Scientific to obtain the proper commercial use license for the Caco-2TM cells.  If you have used Caco-2TM cells commercially without proper authorization, you may be eligible to participate in the CACO-2Up-To-Date program. Please contact NaviCyte Scientific immediately. © 2005 LION bioscience Inc. NaviCyte is a trademark of LION bioscience Inc. CACO-2 is a trademark of the Memorial Sloan-Kettering Cancer Center.